Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a SAD Study of AKB-4924 in Healthy Male Volunteers
NCT02914262Phase 1Completed
- Sponsor
- Aerpio Therapeutics
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing AKB-4924 with Placebo (2 arms). Primary endpoint: Safety and tolerability of AKB-4924 at 8 days. Started Aug 2016; status: completed.
02
Drugs
GB004
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02914262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914262.